HES5 silencing is an early and recurrent change in prostate tumourigenesis.
Massie CE, Spiteri I, Ross-Adams H, Luxton H, Kay J, Whitaker HC, Dunning MJ, Lamb AD, Ramos-Montoya A, Brewer DS, Cooper CS, Eeles R; UK Prostate ICGC Group; Warren AY, Tavaré S, Neal DE, Lynch AG.
Massie CE, et al. Among authors: lynch ag.
Endocr Relat Cancer. 2015 Apr;22(2):131-44. doi: 10.1530/ERC-14-0454. Epub 2015 Jan 5.
Endocr Relat Cancer. 2015.
PMID: 25560400
Free PMC article.